Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04747626

B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair

A prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location status: Recruiting

Location contact

Ali Khalifeh, M. D.

SUB_INVESTIGATOR

Anthony Zaki, M. D.

SUB_INVESTIGATOR

Donna Kilmmaliardjuk, M. D.

SUB_INVESTIGATOR

Edward Soltez, M. D.

SUB_INVESTIGATOR

Eric Roselli, M. D.

CONTACT

[email protected]

216-444-0995

Eric Roselli, M. D.

PRINCIPAL_INVESTIGATOR

Faisal Bakaeen, M. D.

SUB_INVESTIGATOR

Francis Caputo, M. D.

SUB_INVESTIGATOR

Haytham Elgharably, M. D.

SUB_INVESTIGATOR

John Quatromoni, M. D.

SUB_INVESTIGATOR

Lee Kirksey, M. D.

SUB_INVESTIGATOR

Marc Gillinov, M. D.

SUB_INVESTIGATOR

Marijan Koprivanac, M. D.

SUB_INVESTIGATOR

Michael Tong, M. D.

SUB_INVESTIGATOR

Patrick Vargo, M. D.

SUB_INVESTIGATOR

Ravi Ambani, M. D.

SUB_INVESTIGATOR

Sean Steenberge, M. D.

SUB_INVESTIGATOR

Shinya Unai, M. D.

SUB_INVESTIGATOR

Tarek Malas, M. D.

SUB_INVESTIGATOR

Xiaoying Lou, M. D.

SUB_INVESTIGATOR

Yuki Kuramochi, BSN, RN

CONTACT

[email protected]

216-445-4063

About this study

The proposed Investigational Device Exemption (IDE) is to assess the safety and preliminary effectiveness of the simplified hybrid frozen elephant trunk repair technique Branched Stented Anastamosis Frozen Elephant Trunk Repair (B-SAFER) which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments. The study will also evaluate the device functionality when using this operative technique for device implantation including multiple components.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Subject is willing and able to give written informed consent to participate in the study or the subject's legally authorized representative has given written informed consent for the subject to participate in the study.
  • Expected life expectancy of greater than two years after repair
  • Subject has aortic pathology and requires repair or replacement of multiple damaged or diseased segments of the thoracic aorta (at least one of the following condition): Thoracic aortic aneurysm considered at increased risk for rupture or complications, Acute aortic dissection requiring urgent repair, Congenital aortic disease requiring repair

Exclusion criteria

  • Subject is unfit for open surgical repair involving circulatory arrest
  • Subject is comatose or suffering from irreversible severe brain malperfusion
  • Subject has known sensitivity to components of the devices
  • Subject has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
  • Subject is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study
  • Subject has an uncorrectable bleeding anomaly
  • Subject has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- procedure
  • Subject is pregnant

Treatment and study plan

B-SAFER

Device

Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.

Primary outcomes

  1. All-cause mortality

    Time frame: Up to 30 days

    Individual rate of occurrence of the death from all-cause

  2. Stroke, excluding TIA

    Time frame: Up to 30 days

    Individual rate of occurrence of stroke

  3. Paralysis, excluding paraparesis

    Time frame: Up to 30 days

    Individual rate of occurrence of paralysis

  4. Technical success

    Time frame: 24 hours

    Composite of the following criteria: successful delivery of the device through the vasculature, successful deployment of the device at the intended location, and patient survival

  5. Patency of all graft/endograft components

    Time frame: At hospital discharge or at 1 month

    Patent graft/endografts confirmed by CT imaging assessment

  6. Complete sealing of the aortic pathology

    Time frame: At hospital discharge or 1 month

    Absence of Type Ia and IIIa/b endoleak, complete coverage of PAU cases, and isolation of the primary entry tear in dissection cases confirmed by CT imaging assessment

Secondary outcomes

  1. Aortic related death

    Time frame: Up to 36 months after the index procedure

    Individual rate of the aortic related death

  2. Pseudoaneurysm at the treatment sites

    Time frame: Up to 36 months after the index procedure

    Individual rate of the pseudoaneurysm at the treatment sites

  3. Unanticipated aortic or branch-related re-operation

    Time frame: Up to 36 months after the index procedure

    Individual rate of the unanticipated aortic or branch-related re-operation

  4. Late Type I endoleak

    Time frame: Up to 36 months after the index procedure

    Individual rate of the Type I endoleak confirmed by CT imaging assessment

  5. Late Type III endoleak

    Time frame: Up to 36 months after the index procedure

    Individual rate of the Type III endoleak confirmed by CT imaging assessment

  6. Non-cardiac/non-aortic re-operations

    Time frame: Up to 36 months after the index procedure

    Individual rate of non-cardiac/non-aortic re-operations

  7. Vocal Cord paralysis

    Time frame: Up to 36 months after the index procedure

    Individual rate of vocal cord paralysis

  8. Myocardial infarction

    Time frame: Up to 36 months after the index procedure

    Individual rate of myocardial infarction

  9. Respiratory failure

    Time frame: Up to 36 months after the index procedure

    Individual rate of respiratory failure

  10. Renal failure requiring dialysis

    Time frame: Up to 36 months after the index procedure

    Individual rate of renal failure requiring dialysis

  11. Thromboembolic events

    Time frame: Up to 36 months after the index procedure

    Individual rate of thromboembolic events

  12. Failed patencies in graft, or endovascular stent-graft including the branch(es)

    Time frame: Up to 36 months after the index procedure

    Individual rate of failed patencies in gaft or endovascular stent-graft including branch(es)

  13. Secondary unplanned interventions in the treated vascular segment or related to the original pathology

    Time frame: Up to 36 months after the index procedure

    Individual rate of secondary unplanned interventions in the treated vascular segment or related to the original pathology

  14. Aortic rupture

    Time frame: Up to 36 months after the index procedure

    Individual rate of aortic rupture

  15. Device integrity failures

    Time frame: Up to 36 months after the index procedure

    Individual rate of device integrity failures confirmed by CT imaging assessment

  16. Device crimping/kinking

    Time frame: Up to 36 months after the index procedure

    Individual rate of device crimping/kinking confirmed by CT imaging assessment

  17. Device migration

    Time frame: Up to 36 months after the index procedure

    Individual rate of device migration (>10 mm based on the position of the device implantation) compared to baseline confirmed by CT imaging assessment

  18. Thrombosis of the device lumen

    Time frame: Up to 36 months after the index procedure

    Individual rate of thrombosis of the device lumen confirmed by CT imaging assessment

  19. Surgical graft/stentgraft infection

    Time frame: Up to 36 months after the index procedure

    Individual rate of surgical graft/stentgraft infection

  20. Incidence of all endoleak types

    Time frame: Up to 36 months after the index procedure

    Individual rate of all endoleak types confirmed by CT imaging assessment

  21. Migration of the distal extension

    Time frame: Up to 36 months after the index procedure

    Individual rate of distal extension migration (>10 mm based on the position of the device implantation) confirmed by CT imaging assessment

  22. Non-serious and serious adverse events

    Time frame: Up to 36 months after the index procedure

    Individual rate of non-serious adverse events

  23. Failure of device-extension integrity resulting in a compromised seal and blood leakage or movement of the device

    Time frame: Up to 36 months after the index procedure

    Individual rate of the extension device integrity issues confirmed by CT imaging assessment

  24. Incidence of Type III endoleak related to the extension device

    Time frame: Up to 36 months after the index procedure

    Individual rate of the Type III endoleak related to the extension device confirmed by CT imaging assessment

  25. Incidence of failed patency of the device-extension overlap

    Time frame: Up to 36 months after the index procedure

    Individual rate of failed patency of the device-extension overlap confirmed by CT imaging assessment

  26. Incidence of MAE at 30 days post-extension

    Time frame: Up to 36 months after the index procedure

    Individual rate and type of MAE at 30 days post-extension

  27. Incidence of secondary procedures related to the extension

    Time frame: Up to 36 months after the index procedure

    Individual rate secondary procedures related to the extension

Study contacts

Contact information is provided by the study sponsor or research team.

Eric Roselli, M. D.

CONTACT

[email protected]

216-444-0995

Yuki Kuramochi, BSN, RN

CONTACT

[email protected]

2164454063

Sponsors and collaborators

Lead sponsor

Eric Roselli, M. D.

Other

Collaborators

  • The Cleveland Clinic

Registry information

Acronym: B-SAFER

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Feb 10, 2021
Registry last updated
Oct 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.